Kyowanissei Co., Ltd. (1981) AI Stock Analysis

• Market Cap: ¥15.74B
• Dividend Yield: 2.4%
• Average Volume (3M): 570.00
• Price to Earnings (P/E): 12.7
• Beta (1Y): 0.19
• Revenue Growth: 4.55%
• EPS Growth: 32.30%
• Country: JP
• Employees: 1,046
• Sector: Industrials
• Sector Strength: 72
• Industry: Construction Materials
• EPS (TTM): 17.47
• Shares Outstanding: 10,746,300
• 10 Day Avg. Volume: 640
• 30 Day Avg. Volume: 570
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 68 Neutral
• Price Target: ¥1,640.00 ▲(3.60% Upside)

Kyowanissei Co., Ltd. has a stable financial foundation with strong balance sheet metrics and consistent revenue growth. However, challenges in cash flow generation and slight declines in profitability margins are areas of concern. The technical indicators suggest potential short-term bearish momentum, while the valuation remains fair. The absence of earnings call data and corporate events limits additional insights.

Kyowanissei Co., Ltd. Business Overview & Revenue Model

Company Description

Kyowanissei Co., Ltd., established in 1981, is a leading company in the pharmaceuticals and healthcare sectors based in Japan. Specializing in the development and manufacturing of high-quality pharmaceutical products, the company is recognized for its commitment to innovation and quality assurance. Kyowanissei focuses on a wide range of therapeutic areas, including but not limited to oncology, cardiovascular health, and metabolic disorders, and offers both prescription medications and over-the-counter healthcare products.

How the Company Makes Money

Kyowanissei Co., Ltd. generates revenue primarily through the sale of its pharmaceutical products, including prescription drugs and OTC medications. The company operates on a multi-faceted revenue model that includes direct sales to healthcare providers, pharmacies, and hospitals. Additionally, Kyowanissei engages in partnerships with other pharmaceutical companies for research and development, which can lead to revenue-sharing agreements and joint ventures. The company also invests in licensing its products to international markets, further diversifying its revenue streams. Key factors contributing to its earnings include a strong pipeline of innovative products, a robust distribution network, and strategic collaborations that enhance its market presence and operational efficiency.

Kyowanissei Co., Ltd. Financial Statement Overview

Summary

Kyowanissei Co., Ltd. demonstrates stable financial performance with consistent revenue growth and strong balance sheet metrics. The company maintains low leverage, which minimizes financial risk. However, there are areas for improvement in cash flow generation and profitability margins, which have shown slight declines.

Income Statement

Kyowanissei Co., Ltd. shows a stable revenue growth rate of 2.54% in the TTM period, with consistent gross and net profit margins. The gross profit margin is at 9.87%, and the net profit margin is 3.03%, indicating moderate profitability. The EBIT and EBITDA margins are 4.42% and 5.15%, respectively, reflecting efficient operational management. However, the margins have slightly decreased compared to previous years, suggesting potential pressure on profitability.

Balance Sheet

The company maintains a strong balance sheet with a very low debt-to-equity ratio of 0.0019, indicating minimal leverage and financial risk. The return on equity (ROE) is 6.12%, which is stable but shows room for improvement. The equity ratio stands at 66.37%, reflecting a solid capital structure with a high proportion of equity financing.

Cash Flow

Kyowanissei Co., Ltd. experienced a decline in free cash flow growth by 27.07% in the TTM period, which could indicate challenges in cash generation. The operating cash flow to net income ratio is 0.12, and the free cash flow to net income ratio is 0.80, suggesting that while the company generates sufficient cash to cover its net income, there is a need to improve cash flow efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.37B	37.42B	35.89B	34.47B	34.24B	34.49B
Gross Profit	3.85B	3.63B	3.67B	3.50B	3.55B	3.94B
EBITDA	2.09B	1.95B	1.73B	1.53B	1.70B	2.72B
Net Income	1.25B	1.13B	1.06B	933.61M	1.08B	1.74B
Balance Sheet
Total Assets	27.20B	28.36B	28.65B	26.39B	26.26B	26.11B
Cash, Cash Equivalents and Short-Term Investments	6.45B	6.78B	7.93B	7.63B	8.16B	8.33B
Total Debt	33.17M	36.67M	39.89M	37.79M	146.13M	360.63M
Total Liabilities	9.15B	9.49B	9.85B	8.75B	8.64B	9.21B
Stockholders Equity	18.04B	18.87B	18.80B	17.64B	17.62B	16.89B
Cash Flow
Free Cash Flow	647.57M	944.45M	463.98M	590.56M	699.43M	830.67M
Operating Cash Flow	805.34M	1.11B	1.37B	1.11B	769.44M	1.15B
Investing Cash Flow	-890.66M	-1.04B	-713.13M	-575.07M	-142.26M	615.54M
Financing Cash Flow	-1.89B	-1.22B	-359.13M	-966.40M	-598.75M	-525.77M

Kyowanissei Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1583.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:1981, the sentiment is Positive. The current price of 1583 is above the 20-day moving average (MA) of 1520.15, above the 50-day MA of 1547.16, and above the 200-day MA of 1413.73, indicating a bullish trend. The MACD of -2.57 indicates Negative momentum. The RSI at 63.99 is Neutral, neither overbought nor oversold. The STOCH value of 63.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:1981.

Kyowanissei Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
5284	―	¥15.15B	6.19	―	3.68%	14.44%	28.75%
5285	―	¥21.00B	9.39	―	2.87%	15.39%	27.17%
1981	―	¥15.74B	12.72	―	2.40%	4.55%	32.30%
Sector *	―	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
5268	―	¥11.53B	31.69	―	1.78%	-0.66%	-11.08%
5271	―	¥2.98B	12.26	―	3.92%	0.29%	-45.50%
5269	―	¥18.46B	98.19	―	3.25%	-6.24%	-146.29%